CV9201 proven effective in NSCLC: CureVac study
The trial was intended to test the safety and toxicity of CV9201, besides its ability to induce antigen-specific humoral and cellular immune responses in cancer patients. The trial
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.